PRNewswire

• Development of augmented reality head mounted displays using Vuzix waveguide technologies to address pressing challenges

ROCHESTER, N.Y., June 3, 2024 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of smart glasses and Augmented Reality (AR) technology and products, is pleased to announce that it has been selected by AFWERX for a Smart Business Innovative Research (SBIR) Phase I contract focused on the development of... (continue reading...)

–   Phase 1/2 pivotal study met the primary safety and efficacy endpoints –

–   51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; complete responses have been durable beyond 12 months with median duration of follow up of 20 months as of data cutoff –

–   86% of patients (30 out of 35) had a decrease in surgical interventions in the year after PRGN-2012 treatment compared to the year prior... (continue reading...)

Leading global contextual advertising company strengthens CTV offering amid channel growth

NEW YORK, June 3, 2024 /PRNewswire/ -- Seedtag, the global leader in contextual advertising, announced today that the company has acquired Beachfront, the sell-side ad platform built for CTV and streaming. Beachfront's advanced technology, premium inventory, and expertise in CTV advertising will be seamlessly incorporated into Seedtag's existing contextual advertising solutions,... (continue reading...)

Dionis expands into facial skincare category infused with key ingredient, goat milk

BUCKS COUNTY, Pa., June 3, 2024 /PRNewswire/ -- Premiere and best-selling goat milk infused skincare brand, Dionis Goat Milk Skincare, has revolutionized goat milk body care for over 40 years and is now expanding into skincare with the launch of their innovative and powerful Core Collection for the face. Consistent with the existing product range, the category's foundational launch... (continue reading...)

SHANGHAI, June 3, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company, announced today that the preliminary Phase 1/2 clinical data of MHB088C (B7-H3 ADC) was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation.

Abstract #: 3012

Results of a Phase 1/2 Study of MHB088C: a Novel B7-H3 Antibody-Drug Conjugate (ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in... (continue reading...)